The present invention concerns antibody-conjugates comprising an anti-CEACAM5-antibody for use for treating cancer in combination with cetuximab. The invention further relates to pharmaceutical compositions and kit-of-parts comprising an anti-CEA-CAM5-antibody in combination with cetuximab for use for treating cancer.

The present invention provides random copolymers containing zwitterions and one or more functional agents, and methods of preparing such random copolymers.

Provided herein are compositions and methods for modulating internalization properties of cell surface molecules, e.g., converting a non-internalizing cell surface antigen into an internalizing one, and vice versa. In some embodiments, provided are engineered antibodies each containing an antigen binding moiety specific for a guide-antigen and another antigen binding moiety specific for an effector antigen, wherein the internalization property of the engineered antibody or functional fragment thereof is determined by a relative surface density ratio of the guide antigen to the effector antigen. Also provided are recombinant cells, recombinant nucleic acids encoding such engineered antibodies, as well as pharmaceutical compositions containing same. The disclosure also provides methods useful for modulating cellular internalization in a cell or a subject, as well as methods for modulating cell-type selective signaling in a subject and/or for the treatment of diseases.

This disclosure provides NaPi2b-targeted antibody-drug conjugates (e.g., NaPi2b-targeted antibody-polymer-drug conjugates) that specifically bind to the extracellular region of SLC34A2, and to methods of using such conjugates in a variety of therapeutic, diagnostic, and prophylactic indications.

This invention relates to quaternary amine linkers and anti-body drug conjugates thereof, to pharmaceutical compositions containing them, and to their use in therapy for the prevention or treatment of cancer.

The present invention provides engineered polypeptide conjugates (e.g., antibody-drug-conjugates) comprising specific acyl donor glutamine-containing tags and amine donor agents. The invention also provides methods of making such engineered polypeptide conjugates using transglutaminase and methods of using thereof.

This disclosure provides NaPi2b-targeted antibody-drug conjugates (e.g., NaPi2b-targeted antibody-polymer-drug conjugates) that specifically bind to the extracellular region of SLC34A2, and to methods of using such conjugates in a variety of therapeutic, diagnostic, and prophylactic indications.

This disclosure provides novel isoquinolidinobenzodiazepines. These compounds can also be incorporated into antibody-drug conjugates.

The present invention provides engineered polypeptide conjugates (e.g., antibody-drug-conjugates) comprising specific acyl donor glutamine-containing tags and amine donor agents. The invention also provides methods of making such engineered polypeptide conjugates using transglutaminase and methods of using thereof.

The present invention provides engineered polypeptide conjugates (e.g., antibody-drug-conjugates) comprising specific acyl donor glutamine-containing tags and amine donor agents. The invention also provides methods of making such engineered polypeptide conjugates using transglutaminase and methods of using thereof.